Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CDC25A | P30304 | 1/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448106 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Erufosine SCHEMBL52781 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL7068514 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL17817094 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL17817487 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL9027644 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Erufosine SCHEMBL14448104 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Elaidylphosphocholine SCHEMBL12235518 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Elaidylphosphocholine SCHEMBL515227 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL14447795 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238253-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024112654-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024097636-A1 | COMBINATION THERAPY FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4363414-A1 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024086804-A1 | INDOLIZINE DERIVATIVES FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11965178-B2 | Platelets loaded with anti-cancer agents | CELLPHIRE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024077036-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-03-19 | — | — | US | disclosed |
| WO-2020033272-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020028258-A1 | SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019191659-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190256924-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| WO-2019156795-A1 | FLUORESCEIN-SPECIFIC CARS EXHIBITING OPTIMAL T CELL FUNCTION AGAINST FL-PLE LABELLED TUMORS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019067092-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ZENTARIS GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1800684-A1 | Novel alkyl phospholipid derivatives and uses thereof | Zentaris GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158376-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | LPAR3 687/4885LPAR2 603/4885LPAR1 917/4885 |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | PHOSPHO1, PTDSS1, PTDSS2 | LPAR3 82/4885LPAR2 88/4885LPAR1 74/4885 |
| US-20240238253-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | API5, IL5, SRMS | LPAR3 2762/4885LPAR2 3377/4885LPAR1 3624/4885 |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | LPAR3 84/4885LPAR2 67/4885LPAR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.